

Europäisch s Pat ntamt
Europ an Pat nt Office
Offic européen des br v ts



(11)

EP 0 757 984 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

12.02.1997 Bulletin 1997/07

(51) Int Cl.⁶: C07C 311/46, A61K 31/18,
C07D 333/38, C07D 209/20

(21) Application number: 96305805.2

(22) Date of filing: 07.08.1996

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE

(30) Priority: 08.08.1995 JP 222673/95

(71) Applicant: ONO PHARMACEUTICAL CO., LTD.
Chuo-ku Osaka 541 (JP)

(72) Inventors:

- Sakaki, Katsuhito, Ono Pharmaceutical Co., Ltd.
Mishima-gun, Osaka, 618 (JP)
- Kanazawa, Hidekazu,
Ono Pharmaceutical Co., Ltd.
Mishima-gun, Osaka, 618 (JP)

• Sugiura, Tsuneyuki,

Ono Pharmaceutical Co., Ltd.
Mishima-gun, Osaka, 618 (JP)

• Miyazaki, Tohru, Ono Pharmaceutical Co., Ltd.
Mishima-gun, Osaka, 618 (JP)

• Ohno, Hiroyuki, Ono Pharmaceutical Co., Ltd.
Mishima-gun, Osaka, 618 (JP)


(74) Representative: Bentham, Stephen

J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)


(54) Hydroxamic acid derivatives useful for inhibiting gelatinase

(57) The present invention relates to

(i) hydroxamic acid derivatives of the formula (I):



wherein R¹ is hydrogen, or C1-4 alkyl; R² is hydrogen, C1-8 alkyl, phenyl, C1-4 alkyl substituted by phenyl; E is -CONR³-, in which R³ is hydrogen, C1-4 alkyl, etc., -NR³CO-, -CO-O-, -O-CO- etc.; A is hydrogen, C1-8 alkyl, C3-7 cycloalkyl, or Ar; J is bond, C2-4 alkylene etc.; G is -(CH₂)_m-, in which m is 2, 3 or 4; or



in which R⁶ and R⁷ is hydrogen, C1-8 alkyl etc.; and non-toxic salts thereof,

ii) processes for the preparation thereof, and

iii) pharmaceutical agents containing them.

The compounds of formula (I) are useful for prevention and/or treatment of diseases induced by overexpression or excess activity of gelatinases, for example, rheumatoid diseases, arthroseitis, unusual bone resorption, osteoporosis.

EP 0 757 984 A1

sis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cells, autoimmune diseases (Crohn's disease, Sjogren's syndrome etc.), diseases caused by vascular emigration or infiltration of leukocytes, or arterialization in animals including human beings, especially human beings.

Description

This invention relates to hydroxamic acid derivatives. More particularly, this invention relates to :

- (i) hydroxamic acid derivatives of the formula (I) as hereinafter defined, and non-toxic salts thereof,
- (ii) processes for the preparation thereof, and
- (iii) pharmaceutical agents containing them.

The matrix metalloproteinases (MMPs) are neutral metalloproteinases and zinc (Zn^{2+}) is essential in the active site for their activation. They degrade collagen, laminin, proteoglycans, fibronectin, elastin, gelatin etc. under physiological conditions and, therefore, are effective on growth and tissue remodelling of articulation tissue, bone tissue and connective tissue. At least 10 classes of MMPs which differ in primary structure are identified. As common characteristics of these enzymes, MMPs


- (1) have Zn^{2+} in the active site and the activity depends on calcium (Ca^{2+}),
- (2) are secreted as an inactive proenzyme and activated outside of cells,
- (3) have high homology on amino acid sequence,
- (4) have an ability to degrade various extracellular matrix components in vivo,
- (5) are regulated by tissue inhibitors of metalloproteinases (TIMP) which are specific to MMPs.

Recently, it is reported that gelatinases, neutral metalloproteinases classified in MMPs which degrade various extracellular matrices represented by gelatin, are related to various diseases.

Gelatinase inhibitors are useful for prevention and/or treatment of various diseases induced by overexpression or excess activation of gelatinases. Such diseases are, for example, rheumatoid diseases, arthroseitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cells, autoimmune diseases (e.g. Crohn's disease, Sjogren's syndrome), diseases caused by vascular emigration or infiltration of leukocytes, arterIALIZATION.

Some compounds possessing inhibitory activity against gelatinases are known. Much research and development on substrate analogous MMP inhibitors has energetically been carried out [Inhibitors of matrix metalloproteinases (MMPs), Nigel RA Beeley, Phillip RJ Ansell, Andrew JP Docherty et. al., Curr. Opin. Ther. Patents., 4, 7-16 (1994), Current Drugs Ltd ISSN 0962-2594].

For example, in the specification of EP 606046, aryl-sulfonamide derivatives of the formula (X):




wherein (a) Ar^x is carbocyclic or heterocyclic aryl; R^x is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl etc.; R^{1x} is hydrogen, lower alkyl, carbocyclic aryl-lower alkyl etc.; R^{2x} is hydrogen, lower alkyl; or (b) R^x and R^{1x} together with the chain to which they are attached form 1, 2, 3, 4-tetrahydro-isoquinoline, piperidine etc.; Ar^x and R^{2x} are as defined in (a); or (c) R^{1x} and R^{2x} together with the carbon to which they are attached form C3-7 cycloalkane, oxa-cyclohexane, thia-cyclohexane etc. which is unsubstituted or substituted by lower alkyl; and Ar^x and R^{2x} are as defined in (a); *inter alia*, are disclosed to have inhibitory activity against matrix metalloproteinase.

Energetic investigations have been carried out in order to make a gelatinase inhibitor. The present inventors have found that a series of hydroxamic acid derivatives of the formula (I) have inhibitory activity against gelatinases and have accomplished the present invention.

Hydroxamic acid derivatives of the formula (I) of the present invention are novel compounds that are not known at all.

The present invention provides a hydroxamic acid derivative of formula (I):



10 wherein R¹ is hydrogen, or C1-4 alkyl;

R² is (1) hydrogen, (2) C1-8 alkyl, (3) phenyl, or (4) C1-4 alkyl substituted by phenyl;

E is (1) -CONR³-, in which R³ is hydrogen, C1-4 alkyl, phenyl, or C1-4 alkyl substituted by phenyl;

(2) -NR³CO-, in which R³ is as hereinbefore defined;

(3) -CO-O-,

(4) -O-CO-,

(5) -NR³-CO-NR³-, in which R³ is as hereinbefore defined;

(6) -CO-CH₂-,

(7) -CO-,

(8) -O-CO-NR³-, in which R³ is as hereinbefore defined;

(9) -NR³-CO-O-, in which R³ is as hereinbefore defined;

(10) -O-CO-O-,

(11) -CS-NR³-, in which R³ is as hereinbefore defined;

(12) -NR³-CS-, in which R³ is as hereinbefore defined;

(13) -NR³-CS-NR³-, in which R³ is as hereinbefore defined;

(14) -O-CS-NR³-, in which R³ is as hereinbefore defined;

(15) -NR³-CS-O-, in which R³ is as hereinbefore defined;


(16) -CS-O-,

(17) -O-CS-, or

(18) -O-CS-O-,


A is (1) hydrogen, (2) C1-8 alkyl, (3) C3-7 cycloalkyl, or (4) Ar, in which Ar is carbocyclic aryl or heterocyclic aryl, and is unsubstituted or substituted by 1-3 of C1-15 alkyl, C1-15 alkoxy, halogen, nitro, cyano, guanidino, amidino, hydroxy, benzyloxy, -NR⁹R¹⁰, in which R⁹ and R¹⁰ each, independently, is hydrogen or C1-4 alkyl; -COOR¹¹, in which R¹¹ is hydrogen or C1-4 alkyl; trifluoromethyl, phenyl or heterocyclic ring;

J is (1) a bond, (2) C2-4 alkylene, (3) C2-4 alkenylene, or (4)



40 in which R⁴ and R⁵ each, independently, is (i) hydrogen, (ii) C1-4 alkyl, or (iii) C1-4 alkoxy, or R⁴ and R⁵, taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group,

G is (1) -(CH₂)_m-, in which m is 2, 3 or 4, or (2)



50 in which R⁶ and R⁷ each, independently, is (i) hydrogen, (ii) C1-8 alkyl, (iii) -COOR⁸, in which R⁸ is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; (iv) Ar, in which Ar is as hereinbefore defined; (v) heterocyclic ring, (vi) C1-8 alkyl substituted by: -COOR⁸, in which R⁸ is as hereinbefore defined; C1-4 alkoxy; hydroxy; benzyloxy; -NR¹²R¹³, in which R¹² and R¹³ each, independently, is hydrogen or C1-4 alkyl; -NR¹⁴COOR¹⁵, in which R¹⁴ is hydrogen or C1-4 alkyl, and R¹⁵ is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; Ar; or heterocyclic ring; with the proviso that one of the carbon atoms in C1-8 alkyl may be replaced by a sulfur atom; or

55 R⁶ and R⁷, taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group;

with the proviso that, when E is -O-CO-NR³-, -O-CO-O-, -O-CS-NR³- or -O-CS-O-, and J is a bond, A is not hydrogen;

or a non-toxic salt thereof.

The present invention also provides a process for the preparation of a compound of formula (I) or a non-toxic salt thereof.

The present invention also provides a pharmaceutical composition which comprises a compound of formula (I) or a non-toxic salt thereof and a pharmaceutically acceptable carrier.

Unless otherwise specified, all isomers are included in the present invention. For example, alkyl, alkoxy and alkylene include straight and branched isomers. Isomers resulting from the presence of asymmetric carbon(s) e.g. branched alkyl, alkoxy and alkylene are also included within the present invention.

In the formula (I), C1-4 alkyl represented by R¹, R³, R⁴, R⁵, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴ means methyl, ethyl, propyl, butyl and isomeric groups thereof.

In the formula (I), C1-8 alkyl represented by R², R⁶, R⁷, R⁸, R¹⁵, or A means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomeric groups thereof.

In the formula (I), C1-4 alkyl substituted by phenyl represented by R², R³, R⁸, or R¹⁵ means methyl, ethyl, propyl, butyl and isomeric groups thereof substituted by 1 of phenyl.

In the formula (I), C1-4 alkoxy represented by R⁴, R⁵, R⁶ or R⁷ means methoxy, ethoxy, propoxy, butoxy and isomeric groups thereof.

In the formula (I), C1-15 alkyl as a substituent of Ar means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl and isomeric groups thereof.

In the formula (I), C1-15 alkoxy as a substituent of Ar means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy, pentadecyloxy and isomeric groups thereof.

In the formula (I), halogen as a substituent of Ar is fluorine, chlorine, bromine or iodine.

In the formula (I), C2-4 alkylene represented by J means ethylene, trimethylene, tetramethylene and isomeric groups thereof.

In the formula (I), C2-4 alkenylene represented by J means vinylene, propenylene, butenylene, butadienylene and isomeric groups thereof.

In the formula (I), C3-7 cycloalkyl represented by R⁴ and R⁵, taken together with carbon to which they are attached, or by R⁶ and R⁷, taken together with carbon to which they are attached or by A means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

In the formula (I), carbocyclic aryl represented by A, or by Ar in R⁶ or R⁷ preferably means C5-10 carbocyclic aryl, for example, benzene, pentalene, indene, naphthalene, azulene.

In the formula (I), heterocyclic aryl represented by A, or by Ar in R⁶ and R⁷ preferably means C5-15 membered mono- or bi-heterocyclic aryl containing 1-2 of nitrogen and/or 1 of oxygen and/or 1 of sulfur, for example a radical derived from pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepin, oxazepine, thiophene, thian (thiopyran), thiepin, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole or benzoimidazole.

In the formula (I), heterocyclic ring represented by R⁶ or R⁷, or present as a substituent of Ar, preferably means C5-15 membered mono- or bi-heterocyclic ring containing 1-2 of nitrogen and/or 1 of oxygen and/or 1 of sulfur. The heterocyclic ring includes partially or fully saturated analogues of the above C5-15 membered mono- or bi-heterocyclic aryl containing 1-2 of nitrogen and/or 1 of oxygen and/or 1 of sulfur, for example, a radical derived from pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, tetrahydropyrimidine, tetrahydropyridazine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiain (dihydrothiopyran), tetrahydrothiain (tetrahydrothiopyran), dihydrooxazole, tetrahydrooxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, morpholine, thiomorpholine, indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydrobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzothiophene, perhydroisobenzothiophene, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole or perhydrobenzimidazole.

In the present specification, including the claims, it is to be understood that the group E, as written, bonds to benzene ring at the right side and to J at the left side. For example, when E is written as -CO-NR³-, the group AJE-bonded to the benzene ring is AJ-CO-NR³-.

Non-toxic salts of the present invention include all pharmaceutically acceptable salts, for example, general salts,

acid addition salts, hydrate salts.

The compounds of the formula (I) of the present invention may be converted into the corresponding salts. Water-soluble salts are preferred. Suitable salts, for example, include:

salts of alkali metals (e.g. sodium, potassium), salts of alkaline earth metals (e.g. calcium, magnesium), ammonium salts, salts of pharmaceutically acceptable organic amines (e.g. tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris (hydroxymethyl)amine, lysine, arginine, N-methyl-D-glucamine).


The compounds of the formula (I) may be converted into the corresponding acid addition salts. Water-soluble salts are preferred. Suitable salts, for example, include:

salts of inorganic acids e.g. hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, nitrate; salts of organic acids e.g. acetate, trifluoroacetate, lactate, tartarate, oxalate, fumarate, maleate, citrate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, toluenesulphonate, isethionate, glucuronate, gluconate.

The compounds of the formula (I) and salts thereof may be converted into the corresponding hydrates by conventional means.


In the compounds of the present invention of the formula (I), hydroxamic acid derivatives of the following formulae, and non-toxic salts thereof are preferable:

the formula I(1):




wherein A and G are as hereinbefore defined,

the formula I(2):




wherein A and G are as hereinbefore defined,

the formula I(3):




wherein A and G are as hereinbefore defined,

the formula I(4):




wherein A and G are as hereinbefore defined,

the formula I(5):




wherein A and G are as hereinbefore defined,

the formula I(6):




wherein A and G are as hereinbefore defined,

the formula I(7):




wherein A and G are as hereinbefore defined,

the formula I(8):




wherein A and G are as hereinbefore defined,

the formula I(9):




wherein A and G are as hereinbefore defined,

the formula I(10):




wherein A and G are as hereinbefore defined,

the formula I(11):




wherein A and G are as hereinbefore defined,

the formula I(12):




wherein A and G are as hereinbefore defined,

the formula I(13):




wherein A and G are as hereinbefore defined,

the formula I(14):




wherein A and G are as hereinbefore defined,

the formula I(15):




wherein A and G are as hereinbefore defined,

the formula I(16):




wherein A and G are as hereinbefore defined,

the formula I(17):




wherein A and G are as hereinbefore defined,

the formula I(18):




wherein A and G are as hereinbefore defined,

the formula I(19):




wherein R¹ and E are as hereinbefore defined,

the formula I(20):




wherein R¹ and E are as hereinbefore defined,

the formula I(21):




wherein R¹ and E are as hereinbefore defined,

the formula I(22):



wherein R¹ and E are as hereinbefore defined,


the formula I(23):



wherein R¹ and E are as hereinbefore defined.

The preferred specific compounds of the formula (I) are the compounds in Tables 1-23 and non-toxic salts thereof and the compounds described in the Examples.


Table 1



(IA)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 2


























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 3



(IC)

























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 4



No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 5


























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 6



(IF)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 7



(IG)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 8



(IH)

























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 9




No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 10




No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 11




No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 12



No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 13



(IN)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		


Table 14



(IP)

No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 15



(IQ)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 16



(IR)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 17



(IS)
























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 18



(IT)

























No.	A	G
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		

Table 19



NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-O-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂


Table 20



(IW)


NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-O-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂

Table 21




NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-O-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂

Table 22




NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-O-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂

Table 23




NO.	E	R ¹
1	-CO-NH-	CH ₃
2	-CO-NH-	CH(CH ₃) ₂
3	-NH-CO-	CH ₃
4	-NH-CO-	CH(CH ₃) ₂
5	-CO-O-	CH ₃
6	-CO-O-	CH(CH ₃) ₂
7	-O-CO-	CH ₃
8	-O-CO-	CH(CH ₃) ₂
9	-NH-CO-NH-	CH ₃
10	-NH-CO-NH-	CH(CH ₃) ₂
11	-O-CO-O-	CH ₃
12	-O-CO-O-	CH(CH ₃) ₂
13	-O-CO-NH-	CH ₃
14	-O-CO-NH-	CH(CH ₃) ₂
15	-NH-CO-O-	CH ₃
16	-NH-CO-O-	CH(CH ₃) ₂
17	-CO-CH ₂ -	CH ₃
18	-CO-CH ₂ -	CH(CH ₃) ₂
19	-CO-	CH ₃
20	-CO-	CH(CH ₃) ₂
21	-CS-NH-	CH ₃
22	-CS-NH-	CH(CH ₃) ₂
23	-NH-CS-	CH ₃
24	-NH-CS-	CH(CH ₃) ₂
25	-CS-O-	CH ₃
26	-CS-O-	CH(CH ₃) ₂
27	-O-CS-	CH ₃
28	-O-CS-	CH(CH ₃) ₂
29	-NH-CS-NH-	CH ₃
30	-NH-CS-NH-	CH(CH ₃) ₂
31	-O-CS-O-	CH ₃
32	-O-CS-O-	CH(CH ₃) ₂
33	-O-CS-NH-	CH ₃
34	-O-CS-NH-	CH(CH ₃) ₂
35	-NH-CS-O-	CH ₃
36	-NH-CS-O-	CH(CH ₃) ₂

(A) In the compounds of the present invention of the formula (I), the compound in which R² is not hydrogen, and A-J-E-, substituents of Ar in A, and R⁶ and R⁷ in G are not -COOH, -CSOH, amino, hydroxy or a group containing -COOH, -CSOH, amino or hydroxy, that is the compound of the formula (I-A):



wherein G¹, E¹, J¹ and A¹ are as hereinbefore defined for G, E, J and A, with the proviso that A¹-J¹-E¹-, substituents of Ar in A¹, and R⁶ and R⁷ in G¹ are not -COOH, -CSOH, amino, hydroxy or a group containing -COOH, -CSOH, amino or hydroxy, R^{2-A} is C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl, and the other symbols are as hereinbefore defined;

may be prepared by amidation of a compound of the formula (II):



wherein all the symbols are as hereinbefore defined;
with a compound of the formula (III):



wherein all the symbols are as hereinbefore defined.

The method of amidation is known. It includes the method

- (1) via an acyl halide,
- (2) via a mixed acid anhydride,
- (3) using a condensing agent.

These methods are explained as follows.

(1) The method via an acyl halide, for example, may be carried out in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent, using an acid halide (e.g. oxalyl chloride or thionyl chloride) at -20°C to reflux temperature, and the obtained acyl halide derivative may be reacted with an amine in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of a tertiary amine (e.g. pyridine, triethyl amine, dimethyl aniline or dimethylaminopyridine) at 0-40°C.


(2) The method via a mixed acid anhydride may be carried out, for example, by reacting a carboxylic acid with an acid halide (e.g. pivaloyl chloride, tosyl chloride, mesyl chloride, ethyl chloroformate or isobutyl chloroformate) in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent, in the presence of a tertiary amine (e.g. pyridine, triethylamine, dimethylaniline or dimethylaminopyridine) at -20°C-40°C, and the obtained mixed acid anhydride derivative may be reacted with a corresponding amine in an organic solvent (e.g. chloroform, methylene chloride, diethyl ether or tetrahydrofuran) at 0-40°C.

(3) The method using a condensing agent (e.g. 1, 3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino) propyl]carbodiimide (EDC) or 2-chloro-1-methylpyridinium iodide) may be carried out, for example, by reacting a carboxylic acid with an amine in an organic solvent (e.g. chloroform, methylene chloride, dimethylformamide or diethyl ether) or without a solvent, optionally in the presence of a tertiary amine (e.g. pyridine, triethylamine, dimeth-

ylaniline or dimethylaminopyridine) using a condensing agent at 0-40°C.

The reactions described in (1), (2) and (3) be carried out under an inert gas (e.g. argon or nitrogen) to avoid water in order to obtain a preferable result.

(B) In the compounds of the present invention of the formula (I), the compound in which R² is hydrogen, or at least one of A-J-E-, substituents of Ar in A, and R⁶ or R⁷ in G is -COOH, -CSOH, amino, hydroxy or a group containing -COOH, -CSOH, amino or hydroxy, that is the compound of the formula (I-B):



wherein G², E², J² and A² are as hereinbefore defined for G, E, J and A, with the proviso that at least one of A²-J²-E²-, substituents of Ar in A², and R⁶ or R⁷ in G² is -COOH, -CSOH, amino, hydroxy or a group containing -COOH, -CSOH, amino or hydroxy, or R² is hydrogen, and the other symbols are as hereinbefore defined; may be prepared by deprotection under alkaline conditions or acidic conditions, or hydrogenolysis of a compound of the formula (I-A) prepared by the above method.

Deprotection under alkaline conditions, for example, may be carried out in an organic solvent (e.g. methanol, tetrahydrofuran or dioxane), using an alkali metal hydroxide (e.g. potassium hydroxide or sodium hydroxide), an alkaline earth metal hydroxide (e.g. calcium hydroxide) or a carbonate (e.g. sodium carbonate or potassium carbonate), an aqueous solution thereof or mixture thereof at 0-40°C.

Deprotection under acidic conditions, for example, may be carried out in a solvent (e.g. methylene chloride, dioxane, ethyl acetate, acetic acid, water or a mixture of two or more thereof), using an organic acid (e.g. trifluoroacetic acid), or an inorganic acid (e.g. hydrogen chloride or hydrogen bromide) or a mixture thereof at 0-120°C.

Hydrogenolysis, for example, may be carried out in a solvent [e.g. an ether (such as tetrahydrofuran, dioxane, dimethoxyethane or diethyl ether), an alcohol (such as methanol or ethanol), a benzene-type solvent (such as benzene or toluene), an amide (e.g. dimethylformamide), water, ethyl acetate, acetic acid or a mixture of two or more thereof], in the presence of a catalyst (e.g. palladium on carbon, palladium black, palladium hydroxide, platinum dioxide or Raney-nickel), optionally in the presence of an inorganic acid (e.g. hydrochloric acid, sulfuric acid, hypochlorous acid, boric acid or tetrafluoroboric acid) or an organic acid (e.g. acetic acid, p-toluenesulfonic acid, oxalic acid, trifluoroacetic acid or formic acid), at ordinary or elevated pressure of hydrogen gas or ammonium formate at 0-200°C.

As will be apparent to those skilled in the art, t-butyl or benzyl may be used as protecting groups for carboxy or hydroxy, but other groups which may be removed easily and selectively are also preferred. For example, the groups described in T.W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1991, may be used. Benzyloxy-carbonyl or t-butoxycarbonyl may be used as protecting groups for amino, but other groups which may be removed easily and selectively are also preferred. t-Butyl or benzyl may be used as protecting groups of hydroxamic acid, but other groups which may be removed easily and selectively are also preferred. For example, -C(CH₃)₂-OCH₃ may be used.


The desired compound of the present invention may be prepared using these protecting groups.

Besides, the compound of the formula (I-B) may be also prepared by reacting the above compound of the formula (II) with 1,1'-carbonyldiimidazole and hydroxylamine, followed by deprotection if necessary, e.g. deprotection under alkaline conditions or acidic conditions, or hydrogenolysis.


This type of reaction is known, for example, in an organic solvent (e.g. dimethylformamide or tetrahydrofuran), optionally in the presence of an amine (e.g. triethylamine or pyridine) at 0-40°C.


The compounds of the formula (II) may be prepared by known methods, methods described in the following schemes 1-7 or methods described in the Examples.

Scheme 1




Scheme 2




Scheme 3


Scheme 4



BNSDOCID: <EP__0757984A1_I_>




Scheme 7



(II-a), (II-b), (II-c), (II-d), (II-e),
 (II-f), (II-g), (II-h), (II-i), (II-j),
 (II-k), (II-l), (II-m), (II-n), (II-o),
 (II-p), (II-q)

deprotection



In the above schemes, R^P is a carboxyl-protecting group (e.g. benzyl or t-butyl), n is 0 or 1 and the other symbols are as hereinbefore defined.

Each reaction in the above schemes may be carried out by a known method. In the above schemes, the compounds of formulae (IV), (V), (VI), (VII) and (VIII) are known per se or may be prepared by known methods.

In each reaction in the present specification, products may be purified by conventional techniques. For example, purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chromatography, by thin layer chromatography or by column chromatography using silica gel or magnesium silicate, by washing or by recrystallization. Purification may be carried out after each reaction, or after a series of reactions.

The other starting materials and reagents in the present invention are known per se or may be prepared by known methods.

The potency of inhibitory activity against each matrix metalloproteinase is confirmed as below. The IC_{50} value for inhibition of gelatinase A activity is determined as follows.

(1) Inhibitory activity against gelatinase A

Progelatinase A ($7\mu\text{l}$; in assay buffer ($90\mu\text{l}$)) was purified from human normal skin dermal fibroblasts (HNDF). It was activated by the addition of 10mM p-aminophenylmercuric acetate (APMA) ($10\mu\text{l}$) for 1 hour at 37°C .

The solution of activated gelatinase A ($7\mu\text{l}/\text{tube}$, $98\mu\text{l}$) was mixed with various concentrations of the test compound or dimethylsulfoxide ($2\mu\text{l}$) and gelatin ($100\mu\text{l}$) labeled with 0.05% fluorescein isothiocyanate (FITC) and incubated for 2 hours at 37°C . The reaction was terminated by the addition of 0.1M Tris-HCl (pH9.5) containing 94.7% ethanol ($750\mu\text{l}$). The mixture was stirred and then allowed to stand for 30 minutes at 0°C . The mixture was centrifuged for 30 minutes at $900\times g$. The IC_{50} was determined by measuring the fluorescent intensity in the supernatant ($Ex = 495\text{nm}$, and $Em = 520\text{nm}$). The results are shown in Table 24 (Example number 2 and 2(3)).

Alternatively the inhibitory activity of the test compound was measured by using the synthetic substrate (MOCAc-Pro-Leu-Gly-Leu-A₂pr(Dnp)-Ala-Arg-NH₂). The substrate solution (890μl; the final concentration was 13.5μM) was mixed with various concentrations of the test compound or dimethylsulfoxide (10ml) for 5 minutes at 37°C. The activated gelatinase A (7μl/tube, 100μl) was added to the reaction mixture and further incubated for 20 minutes at 37°C. 0.1M sodium acetate buffer (2ml; pH4.0) was added into the mixture. The IC₅₀ was determined by measuring the fluorescent intensity (Ex = 328nm, and Em = 393nm) in this solution. The results are shown in Table 24 (Example number 2(4) and 3(2)).

Table 24

Example No.	IC ₅₀ (μM)
2	0.0017
2(3)	0.0010
2(4)	0.00061
3(2)	0.00023

The toxicity of the compounds of the present invention is very low and therefore the compounds may be considered safe for pharmaceutical use.

Inhibition of gelatinases is useful for prevention and/or treatment of diseases induced by overexpression or excess activity of gelatinases, for example, rheumatoid diseases, arthroseitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cells, autoimmune disease (e.g. Crohn's disease, Sjogren's syndrome), disease caused by vascular emigration or infiltration of leukocytes, arterialization in animals including human beings, especially human beings.

For the purpose above described, the compounds of the formula (I), of the present invention, non-toxic salts thereof (e.g. acid addition salts or hydrates) may normally be administered systemically or locally, usually by oral or parenteral administration.

The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment. In the human adult, the doses per person are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration for from 1 to 24 hours per day from vein.

As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

The compounds of the present invention may be administered in the form of, for example, solid compositions, liquid compositions or other compositions for oral administration, injections, liniments or suppositories for parenteral administration.

Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules.

Capsules include hard capsules and soft capsules.

In such compositions, one or more of the active compound(s) may be admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone or magnesium metasilicate aluminate). The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents (such as magnesium stearate), disintegrating agents (such as cellulose calcium glycolate), stabilizing agents, and agents to assist dissolution (such as glutamic acid or aspartic acid).

The tablets or pills may, if desired, be coated with a film of gastric or enteric material (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.

Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, syrups and elixirs. In such compositions, one or more of the active compound(s) may be contained in inert diluent(s) commonly used in the art (e.g. purified water or ethanol). Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents or suspending agents), sweetening agents, flavouring agents, perfuming agents, and preserving agents.

Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (such sodium sulfate), isotonic buffers (such as sodium chloride, sodium citrate or citric acid). For preparation of such spray compositions, for example, the method described in the United

States Patent No. 2,868,691 or 3,095,355 may be used.

Injectons for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Aqueous solutions and suspensions include distilled water for injection and physiological salt solution. Non-aqueous solutions and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, alcohol such as ethanol or POLYSORBATE80 (registered trade mark).

Injectons may comprise additional ingredients other than inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agents, assisting agents such as agents to assist dissolution (e.g. glutamic acid or aspartic acid).

They may be sterilized for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They may also be manufactured in the form of sterile solid compositions which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before use.

Other compositions for parenteral administration include liquids for external use, and endermic liniments, ointment, suppositories for rectal administration and pessaries for vaginal administration which comprise one or more of the active compound(s) and may be prepared by methods known *per se*.

Reference example and Example


The following reference examples and examples illustrate the present invention, but do not limit the present invention.

The solvents in parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations or TLC.

The solvents in parentheses in NMR show the solvents used in measurement.

Reference example 1

N-[(4-Nitrophenyl)sulfonyl]glycine t-butyl ester




4-Nitrobenzenesulfonyl chloride (46.3 g) was added to a solution of glycine t-butyl ester hydrochloride (35 g) in pyridine (200 ml). The mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated. The residue was washed with water and then a mixture of hexane and ethyl acetate (9 : 1) and dried to give the title compound (61.4 g) having the following physical data.

TLC: Rf 0.18 (Hexane : Ethyl acetate = 4 : 1).

Reference example 2

N-[(4-Aminophenyl)sulfonyl]glycine t-butyl ester




To a solution of the compound prepared in reference example 1 (57.1 g) in ethanol (200 ml) and tetrahydrofuran (200 ml), 10% palladium carbon (2.2 g) was added. The mixture was stirred at room temperature for 3 hours under an atmosphere of hydrogen. The reaction mixture was filtered through celite (registered trade mark). The filtrate was concentrated. The residue was washed with a mixture of hexane and ethyl acetate (4 : 1) and dried to give the title compound (50 g) having the following physical data.

TLC: Rf 0.36 (Hexane : Ethyl acetate = 1 : 1).

Reference example 3

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]glycine t-butyl ester



To a solution of the compound prepared in reference example 2 (1.2 g) in pyridine (10 ml), p-toluoyl chloride (0.5 ml) was added at 0°C. The mixture was stirred at room temperature for 30 minutes. To the reaction mixture, 1 N hydrochloric acid (100 ml) was added. The mixture was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium bicarbonate, a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated. The residue was washed with ether and dried to give the title compound (1.52 g) having the following physical data.

TLC: Rf 0.56 (Hexane : Ethyl acetate = 1 : 1),


NMR (CDCl₃): δ 8.08-8.00 (1H, br.s), 7.86 (2H, d, J=9.2Hz), 7.82 (2H, d, J=9.2Hz), 7.78 (2H, d, J=8.2Hz), 7.31 (2H, d, J=8.2Hz), 5.04 (1H, t, J=5.4Hz), 3.67 (2H, d, J=5.4Hz), 2.44 (3H, s), 1.37 (9H, s).

Reference example 3(1)-3(7)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of reference example 3, using a corresponding compound.

Reference example 3(1)

N-[[4-(Benzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.70 (Ethyl acetate),

NMR (CDCl₃): δ 8.02 (1H, s), 7.9-7.8 (6H, m), 7.6-7.3 (3H, m), 5.02 (1H, t, J=5.4Hz), 3.68 (2H, d, J=5.4Hz), 1.37 (9H, s).

Reference example 3(2)

N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.40 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 7.94-7.90 (1H, br.s), 7.86 (2H, d, J=9.2Hz), 7.85 (2H, d, J=8.8Hz), 7.79 (2H, d, J=9.2Hz), 6.99 (2H, d, J=8.8Hz), 5.00 (1H, t, J=5.4Hz), 3.89 (3H, s), 3.67 (2H, d, J=5.4Hz), 1.37 (9H, s).

Reference example 3(3)

N-[[4-(4-Pentylbenzoylamino)phenyl]sulfonyl]-D-phenylalanine t-butyl ester




TLC: Rf 0.66 (Hexane : Ethyl acetate = 3 : 2),

NMR (CDCl₃): δ 7.95 (1H, s), 7.84-7.68 (6H, m), 7.35-7.08 (7H, m), 5.10 (1H, d, J=10.0Hz), 4.14-4.00 (1H, m), 3.02 (2H, d, J=6.0Hz), 2.67 (2H, t, J=7.8Hz), 1.72-1.56 (2H, m), 1.48-1.25 (4H, m), 1.21 (9H, s), 0.89 (3H, t, J=5.0Hz).

Reference example 3(4)

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]-D-tryptophan benzyl ester




TLC: Rf 0.32 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃ + CD₃OD): δ 7.81 (2H, d, J=8.0Hz), 7.56 (4H, s), 7.43 (1H, d, J=7.0Hz), 7.35-7.25 (6H, m), 7.15-7.00 (4H, m), 6.81 (1H, s), 4.92 (2H, s), 4.25 (1H, m), 3.18 (2H, m), 2.45 (3H, s).

Reference example 3(5)

N-[[3-(Benzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.65 (Hexane : Ethyl acetate = 1 : 1),

NMR (CDCl₃): δ 8.26-8.16 (2H, m), 8.00 (1H, t, J=1.8Hz), 7.94-7.87 (2H, m), 7.66-7.46 (5H, m), 5.24 (1H, t, J=5.4Hz), 3.70 (2H, d, J=5.4Hz), 1.35 (9H, s).

Reference example 3(6)

N-[[2-(Benzoylamino)phenyl]sulfonyl]glycine t-butyl ester




TLC: Rf 0.51 (Hexane : Ethyl acetate = 3 : 2),

NMR (CDCl₃): δ 10.27 (1H, s), 8.73 (1H, d, J=8.4Hz), 8.05-7.94 (2H, m), 7.90 (1H, dd, J=1.8Hz, 8.0Hz), 7.70-7.45 (4H, m), 7.30-7.18 (1H, m), 5.20 (1H, t, J=5.2Hz), 3.61 (2H, d, J=5.2Hz), 1.33 (9H, s).

Reference example 3(7)

N-[[4-(2-Thienylcarbonylamino)phenyl]sulfonyl]-D-alanine t-butyl ester




TLC : Rf 0.25 (Hexane : Ethyl acetate = 2 : 1),

NMR (DMSO-d₆): δ 10.51 (1H, s), 8.12-8.05 (2H, m), 7.94-7.88 (3H, m), 7.74 (2H, d, J=8.8Hz), 7.24 (1H, t, J=3.8Hz), 3.72 (1H, quint, J=7.4Hz), 1.27 (9H, s), 1.14 (3H, d, J=7.4Hz).

Reference example 4

N-[[4-(p-Toluoylamino)phenyl]sulfonyl]glycine



A mixture of the compound prepared in reference example 3 (1.45 g) in trifluoroacetic acid (10 ml) and water (1 ml) was stirred at room temperature for 1 hour. The reaction mixture was concentrated. The residue was washed with ether and dried to give the title compound (1.16 g) having the following physical data.

TLC: Rf 0.48 (Chloroform : Methanol : acetic acid = 16 : 3 : 1),


NMR (DMSO-d₆): δ 10.46 (1H, s), 8.02-7.84 (1H), 7.97 (2H, d, J=9.0Hz), 7.88 (2H, d, J=8.0Hz), 7.75 (2H, d, J=9.0Hz), 7.34 (2H, d, J=8.0Hz), 3.55 (2H, d, J=6.2Hz), 2.40 (3H, s).

Reference example 4(1)-4(7)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of reference example 4 or by means of a different deprotection method (e.g. hydrogenolysis), using the compound prepared in reference example 3(1)-3(7) instead of the compound prepared in reference example 3.

Reference example 4(1)


N-[[4-(Benzoylamino)phenyl]sulfonyl]glycine



TLC: Rf 0.19 (Chloroform : Methanol : Acetic acid : Water = 50 : 10 : 1 : 1),
 NMR (CD₃OD): δ 8.0-7.8 (6H, m), 7.6-7.5 (3H, m), 3.70 (2H, s).

Reference example 4(2)


N-[[4-(4-Methoxybenzoylamino)phenyl]sulfonyl]glycine



TLC: Rf 0.43 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),
 NMR (DMSO-d₆): δ 10.39 (1H, s), 7.97 (2H, d, J=8.8Hz), 7.95 (2H, d, J=9.0Hz), 7.89 (1H, t, J=6.2Hz), 7.75 (2H, d, J=9.0Hz), 7.70 (2H, d, J=8.8Hz), 3.84 (3H, s), 3.55 (2H, d, J=6.2Hz).

Reference example 4(3)


N-[[4-(4-Pentylbenzoylamino)phenyl]sulfonyl]-D-phenylalanine



TLC: Rf 0.21 (Chloroform : Methanol : Acetic acid = 95 : 4 : 1),
 NMR (DMSO-d₆): δ 13.00-12.20 (1H, br.s), 10.40 (1H, s), 8.11 (1H, d, J=9.0Hz), 7.88 (2H, d, J=8.6Hz), 7.84 (2H, d, J=8.4Hz), 7.52 (2H, d, J=8.6Hz), 7.34 (2H, d, J=8.4Hz), 7.28-7.08 (5H, m), 3.92-3.78 (1H, m), 2.93 (1H, dd, J=5.8, 13.4Hz), 2.71 (1H, dd, J=8.8, 13.4Hz), 2.66 (2H, t, J=8.2Hz), 1.70-1.50 (2H, m), 1.44-1.18 (4H, m), 0.87 (3H, t, J=6.8Hz).

Reference example 4(4)

N-[[4-(p-Toluylamino)phenyl]sulfonyl]-D-tryptophan




TLC: Rf 0.13 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),

NMR (DMSO-d₆): δ 12.57 (1H, br.s), 10.8 (1H, s), 10.42 (1H, s), 8.13 (1H, d, J=8.8Hz), 7.9-7.8 (4H, m), 7.59 (2H, d, J=8.8Hz), 7.4-7.25 (4H, m), 7.1-6.9 (3H, m), 3.95-3.85 (1H, m), 3.04 (1H, dd, J=6.0, 18.0Hz), 2.84 (1H, dd, J=7.4, 18.0Hz), 2.39 (3H, s).

Reference example 4(5)

N-[[3-(Benzoylamino)phenyl]sulfonyl]glycine




TLC: Rf 0.36 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),

NMR (DMSO-d₆): δ 10.54 (1H, s), 8.33 (1H, s), 8.14-7.90 (4H, m), 7.68-7.44 (5H, m), 3.60 (2H, d, J=6.0Hz).

Reference example 4(6)

N-[[2-(Benzoylamino)phenyl]sulfonyl]glycine




TLC : Rf 0.34 (Chloroform : Methanol : Acetic acid = 90 : 10 : 1),

NMR (DMSO-d₆): δ 13.00-12.60 (1H, br.s), 10.26 (1H, s), 8.67-8.56 (1H), 8.52-8.44 (1H, m), 8.02-7.92 (2H, m), 7.87 (1H, dd, J=1.4, 7.8Hz), 7.74-7.54 (4H, m), 7.38-7.27 (1H, m), 3.65 (2H, d, J=4.6Hz).

Reference example 4(7)

N-[[4-(2-Thienylcarbonylamino)phenyl]sulfonyl]-D-alanine




TLC: Rf 0.21 (Chloroform : Methanol : Water = 4 : 1 : 0.1),

NMR (DMSO-d₆): δ 12.60 (1H, br.s), 10.49 (1H, s), 8.05-7.98 (2H, m), 7.91-7.85 (3H, m), 7.73 (2H, d, J=8.8Hz), 7.21 (1H, t, J=3.8Hz), 3.77-3.68 (1H, m), 1.13 (3H, d, J=7.2Hz).

Example 1

N-Benzyloxy-N'-[[4-(p-Toluoylamino)phenyl]sulfonyl]glycyl]amide



N-Benzyloxy-N'-[[4-(p-Toluoylamino)phenyl]sulfonyl]glycyl]amide (192 mg), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (230 mg), 1-hydroxybenzotriazole (199 mg) and triethylamine (0.34 ml) were added, successively, to a solution of the compound prepared in reference example 4 (348 mg) in N, N-dimethylformamide (5 ml). The mixture was stirred at room temperature overnight. The reaction mixture was concentrated. Ethyl acetate was added into the residue. The solution was washed with 1 N hydrochloric acid, water, aqueous solution of sodium carbonate and water, and then dried and concentrated. The residue was washed with ether and dried to give the title compound (417mg) having the following physical data.

TLC ; Rf 0.52 (Chloroform : Methanol : Acetic acid = 9 : 1 : 0.5),


NMR (DMSO-d₆+CCl₄): δ 11.17 (1H, s), 10.48 (1H, s), 7.98 (2H, d, J=8.8Hz), 7.87 (2H, d, J=7.8Hz), 7.76 (2H, d, J=8.8Hz), 8.1-7.7 (1H, br.s), 7.50-7.25 (7H, m), 4.66 (2H, s), 2.40 (2H, s).

Example 1(1)-1(4)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of example 1, using the compound prepared in reference example 4(1)-4(4) instead of the compound prepared in reference example 4.

Example 1(1)

N-Benzyloxy-N'-[[4-(benzoylamino)phenyl]sulfonyl]glycyl]amide




EP 0 757 984 A1

TLC : Rf 0.38 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),
NMR (CDCl₃+CD₃OD) : δ 7.95-7.8 (6H, m), 7.6-7.45 (3H, m), 7.37 (5H, s), 4.79 (2H, s), 3.50 (2H, s).

Example 1(2)


N-Benzyloxy-N-[N'-[[4-(4-methoxybenzoylamino)phenyl]sulfonyl]glycyl]amide



TLC : Rf 0.52 (Chloroform : Methanol = 9 : 1),
NMR (d₆-DMSO): δ 11.17 (1H, s), 10.41 (1H, s), 8.04-7.84 (1H), 7.97 (2H, d, J=8.8Hz), 7.95 (2H, d, J=8.8Hz), 7.75 (2H, d, J=8.8Hz), 7.42-7.28 (5H, m), 7.07 (2H, d, J=8.8Hz), 4.66 (2H, s), 3.84 (3H, s), 3.40-3.30 (2H).

Example 1(3)


N-Benzyloxy-N-[N'-[[4-(4-pentylbenzoylamino)phenyl]sulfonyl]-D-phenylalanyl]amide



TLC : Rf 0.54 (Chloroform : Methanol = 19 : 1),
NMR (DMSO-d₆): δ 11.21 (1H, s), 10.43 (1H, s), 8.23 (1H, d, J=9.0Hz), 7.89 (2H, d, J=8.8Hz), 7.83 (2H, d, J=8.4Hz), 7.62 (2H, d, J=8.8Hz), 7.40-7.08 (12H, m), 4.41 (1H, d, J=11.0Hz), 4.34 (1H, d, J=11.0Hz), 3.85-3.68 (1H, m), 2.79 (1H, dd, J=6.8, 13.6Hz), 2.73-2.60 (1H), 2.65 (2H, t, J=8.2Hz), 1.70-1.50 (2H, m), 1.45-1.20 (4H, m), 0.86 (3H, t, J=6.6Hz).

Example 1(4)

N-Benzyloxy-N-[N'-[[4-(p-toluoylamino)phenyl]sulfonyl]-D-tryptophyl]amide




TLC : Rf 0.36 (Chloroform : Methanol = 9 : 1),

NMR (DMSO-d₆): δ 11.19 (1H, s), 10.80 (1H, s), 10.41 (1H, s), 8.16 (1H, d, J=8.2Hz), 7.84 (4H, m), 7.65 (2H, d, J=8.8Hz), 7.36-6.92 (12H, m), 4.39 (1H, d, J=13.9Hz), 4.30 (1H, d, J=13.9Hz), 3.78 (1H, q, J=8.2Hz), 3.05-2.70 (2H, m), 2.40 (3H, s).

Example 2

N-Hydroxy-N-[N'-[[4-(p-toluylamino)phenyl]sulfonyl]glycyl]amide



10% Palladium carbon (30 mg) was added to a solution of the compound prepared in example 1 (150 mg) in N, N-dimethylformamide (10 ml). The mixture was stirred at room temperature for 2 hour, under atmosphere of hydrogen. The reaction mixture was filtered through celite and the filtrate was concentrated. Ether was added into the residue, and the crystals which appeared were collected by filtration and dried to give the title compound (80 mg) having the following physical data.

TLC : Rf 0.21 (Chloroform : Methanol : Acetic acid = 9 : 1 : 0.5),


NMR (CD₃OD+DMSO-d₆): δ 8.10-7.70 (6H, m), 7.34 (2H, d, J=7.81Hz), 3.48 (2H, s), 2.43 (3H, s).

Example 2(1)-2(4)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of example 2, using the compound prepared in example 1(1)-1(4) instead of the compound prepared in example 1.

Example 2(1)

N-Hydroxy-N-[N'-[[4-(benzoylamino)phenyl]sulfonyl]glycyl]amide




TLC : Rf 0.04 (Chloroform : Methanol : Acetic acid : Water = 100 : 10 : 1 : 1),

NMR (DMSO-d₆): δ 10.58 (1H, s), 10.53 (0.5H, s), 8.86 (0.5H, s), 8.0-7.95 (4H, m), 7.9-7.75 (2H, m), 7.6-7.5 (3H, m), 3.33 (2H, s).

Example 2(2)

N-Hydroxy-N-[N'-[[4-(4-methoxybenzoylamino)phenyl]sulfonyl]glycyl]amide




TLC: Rf 0.38 (Chloroform: Methanol: Acetic acid = 16: 3: 1),

NMR (DMSO-d6): δ 10.52 (1H, s), 10.40 (1H, s), 8.86 (1H, s), 7.97 (4H, d, J=8.8Hz), 7.90-7.70 (1H), 7.76 (2H, d, J=8.8Hz), 7.07 (2H, d, J=8.8Hz), 3.85 (3H, s), 3.40-3.10 (2H).

Example 2(3)

N-Hydroxy-N-[N'-[[4-(4-pentylbenzoylamino)phenyl]sulfonyl]-D-phenylalanyl]amide




TLC : Rf 0.42 (Chloroform : Methanol = 9 : 1),

NMR (DMSO-d6): δ 10.41 (1H, s), 7.88 (2H, d, J=8.4Hz), 7.84 (2H, d, J=8.4Hz), 7.54 (2H, d, J=8.4Hz), 7.35 (2H, d, J=8.4Hz), 7.26-7.00 (5H, m), 3.77 (1H, t, J=6.6Hz), 2.90-2.72 (1H, m), 2.72-2.56 (3H, m), 1.70-1.50 (2H, m), 1.50-1.10 (4H, m), 0.87 (3H, t, J=6.8Hz).

Example 2(4)

N-Hydroxy-N-[N'-[[4-(p-tolucylamino)phenyl]sulfonyl]-D-tryptophyl]amide




TLC : Rf 0.59 (Chloroform : Methanol = 4 : 1),

NMR (DMSO-d6): δ 10.74 (1H, s), 10.59 (1H, s), 10.38 (1H, s), 8.80 (1H, s), 8.02-7.80 (5H, m), 7.58 (2H, d, J=8.6 Hz), 7.38-7.23 (4H, m), 7.00-6.85 (1H, m), 3.90-3.74 (1H, m), 3.04-2.90 (1H, m), 2.75-2.61 (1H, m), 2.40 (3H, s).

Example 3

N-Hydroxy-N-[N'-[[3-(benzoylamino)phenyl]sulfonyl]glycyl]amide



1, 1'-Carbonyldiimidazole (265 mg) was added to a solution of the compound prepared in reference example 4(5) (500 mg) in tetrahydrofuran (15 ml). The mixture was stirred at room temperature for 7 hours. Hydroxylamine hydrochloride (213 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 18 hours. 1N Hydrochloric acid was added to the reaction mixture. The mixture was extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried and concentrated. The residue was washed with ether and dried to give the title compound (391 mg) having the following physical data.

TLC : Rf 0.46 (Chloroform : Methanol : Acetic acid = 16 : 3 : 1),


NMR (DMSO-d₆): δ 10.55 (2H, s), 8.88 (1H, s), 8.33 (1H, s), 8.09-7.90 (4H, m), 7.64-7.48 (5H, m), 3.40-3.30 (2H).

Example 3(1)-3(2)

The compounds having the following physical data were obtained by the same procedure as a series of reactions of example 3, using the compound prepared in reference example 4(6) and 4(7) instead of the compound prepared in reference example 4(5).

Example 3(1)

N-Hydroxy-N-[N'-[[2-(benzoylamino)phenyl]sulfonyl]glycyl]amide




TLC : Rf 0.40 (Ethyl acetate),

NMR (DMSO-d₆): δ 10.60 (1H, s), 10.32 (1H, s), 9.05-8.80 (1H, br.s), 8.57 (1H, t, J=6.0Hz), 8.50-8.41 (1H, m), 8.03-7.93 (2H, m), 7.90-7.82 (1H, m), 7.74-7.52 (4H, m), 7.40-7.28 (1H, m), 3.41 (2H, d, J=6.0Hz).

Example 3(2)

N-Hydroxy-N-[N'-[[2-(2-thienylcarbonylamino)phenyl]sulfonyl]-D,L-alanyl]amide



TLC : Rf 0.48 (Chloroform : Methanol = 4 : 1),

NMR (DMSO-d₆): δ 10.57 (1H, br.s), 8.84 (1H, d, J=2.2Hz), 8.11 (1H, d, J=3.6Hz), 7.97-7.88 (5H, m), 7.76 (2H, d, J=8.8Hz), 7.24 (1H, t, J=3.6Hz), 3.68-3.61 (1H, m), 1.02 (3H, d, J=7.2Hz).

Formulation example 1

The following components were admixed in conventional method and punched out to obtain 100 tablets each containing 50 mg of active ingredient.

- N-Hydroxy-N-[N'-[[4-(p-toluoylamino)phenyl]sulfonyl]glycyl]amide 5g
- Carboxymethyl Cellulose calcium (disintegrating agent) 0.2g
- Magnesium stearate (lubricating agent) 0.1 g
- Microcrystalline cellulose 4.7g


Formulation example 2

The following components were admixed in conventional method. The solution was sterilized in conventional manner, placed 2 ml portions into 5 ml ampoules and freeze-dried to obtain 100 ampoules each containing 20 mg of the active ingredient.

- N-Hydroxy-N-[N'-[[4-(p-toluoylamino)phenyl]sulfonyl]glycyl]amide 2.00g
- mannitol 20 g
- distilled water 500 ml

Claims

1. A hydroxamic acid derivative of formula (I):



wherein R¹ is hydrogen, or C1-4 alkyl;

R² is (1) hydrogen, (2) C1-8 alkyl, (3) phenyl, or (4) C1-4 alkyl substituted by phenyl;

E is (1) -CONR³-, in which R³ is hydrogen, C1-4 alkyl, phenyl, or C1-4 alkyl substituted by phenyl;

(2) -NR³CO-, in which R³ is as hereinbefore defined;

(3) -CO-O-,

(4) -O-CO-,

(5) -NR³-CO-NR³-, in which R³ is as hereinbefore defined;

(6) -CO-CH₂-,

(7) -CO-,

(8) -O-CO-NR³-, in which R³ is as hereinbefore defined;

(9) -NR³-CO-O-, in which R³ is as hereinbefore defined;

(10) -O-CO-O-,

(11) -CS-NR³-, in which R³ is as hereinbefore defined;

(12) -NR³-CS-, in which R³ is as hereinbefore defined;

(13) -NR³-CS-NR³-, in which R³ is as hereinbefore defined;

(14) -O-CS-NR³-, in which R³ is as hereinbefore defined;

(15) -NR³-CS-O-, in which R³ is as hereinbefore defined;


(16) -CS-O-,

(17) -O-CS-, or


(18) -O-CS-O-,

A is (1) hydrogen, (2) C1-8 alkyl, (3) C3-7 cycloalkyl, or (4) Ar, in which Ar is carbocyclic aryl or heterocyclic aryl, and is unsubstituted or substituted by 1-3 of C1-15 alkyl, C1-15 alkoxy, halogen, nitro, cyano, guanidino, amidino, hydroxy, benzyloxy, -NR⁹R¹⁰, in which R⁹ and R¹⁰ each, independently, is hydrogen or C1-4 alkyl; -COOR¹¹, in which R¹¹ is hydrogen or C1-4 alkyl; trifluoromethyl, phenyl or heterocyclic ring;

J is (1) a bond, (2) C2-4 alkylene, (3) C2-4 alkenylene, or (4)



in which R^4 and R^5 each, independently, is (i) hydrogen, (ii) C1-4 alkyl, or (iii) C1-4 alkoxy, or R^4 and R^5 , taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group,
G is (1) $-(CH_2)_m-$, in which m is 2, 3 or 4, or (2)




in which R^6 and R^7 each, independently, is (i) hydrogen, (ii) C1-8 alkyl, (iii) $-COOR^8$, in which R^8 is hydrogen, C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl; (iv) Ar, in which Ar is as hereinbefore defined; (v) heterocyclic ring; (vi) C1-8 alkyl substituted by: $-COOR^8$, in which R^8 is as hereinbefore defined; C1-4 alkoxy; hydroxy; benzyloxy; $-NR^{12}R^{13}$, in which R^{12} and R^{13} each, independently, is hydrogen or C1-4 alkyl; $-NR^{14}COOR^{15}$, in which R^{14} is hydrogen or C1-4 alkyl and R^{15} is hydrogen, C1-8 alkyl, phenyl or C1-4 alkyl substituted by phenyl; Ar; or heterocyclic ring; with the proviso that one of the carbon atoms in C1-8 alkyl may be replaced by a sulfur atom; or R^6 and R^7 , taken together with the carbon to which they are attached, form a C3-7 cycloalkyl group;
with the proviso that, when E is $-O-CO-NR^3-$, $-O-CO-O-$, $-O-CS-NR^3-$ or $-O-CS-O-$, and J is a bond, A is not hydrogen;
or a non-toxic salt thereof.

2. A compound according to claim 1, wherein E is $-CONR^3-$, $-NR^3CO-$, $-NR^3CO-NR^3-$, $-O-CO-NR^3-$, $-NR^3CO-O-$, $-CS-NR^3-$, $-NR^3CS-$, $-NR^3CS-NR^3-$, $-O-CS-NR^3-$, or $-NR^3CS-O-$.
3. A compound according to claim 1, wherein E is $-CO-O-$, $-O-CO-$, $-CO-CH_2-$, $-CO-$, $-O-CO-O-$, $-CS-O-$, $-O-CS-$, or $-O-CS-O-$.
4. A compound according to claim 1, which is selected from N-Benzyloxy-N-[N'-[[4-(p-Toluylamino)phenyl]sulfonyl]glycyl]amide, N-Benzyloxy-N-[N'-[[4-(benzoylamino)phenyl]sulfonyl]glycyl]amide, N-Benzyloxy-N-[N'-[[4-(4-methoxybenzoylamino)phenyl]sulfonyl]glycyl]amide, N-Benzyloxy-N-[N'-[[4-(4-pentylbenzoylamino)phenyl]sulfonyl]-D-phenylalanyl]-amide, N-Benzyloxy-N-[N'-[[4-(p-toluylamino)phenyl]sulfonyl]glycyl]amide, N-Hydroxy-N-[N'-[[4-(benzoylamino)phenyl]sulfonyl]glycyl]amide, N-Hydroxy-N-[N'-[[4-(4-methoxybenzoylamino)phenyl]sulfonyl]glycyl]amide, N-Hydroxy-N-[N'-[[4-(4-pentylbenzoylamino)phenyl]sulfonyl]-D-phenylalanyl]amide, N-Hydroxy-N-[N'-[[4-(p-toluylamino)phenyl]sulfonyl]-D-tryptophyl]amide, N-Hydroxy-N-[N'-[[3-(benzoylamino)phenyl]sulfonyl]glycyl]amide, N-Hydroxy-N-[N'-[[2-(benzoylamino)phenyl]sulfonyl]glycyl]amide, and N-Hydroxy-N-[N'-[[2-(2-thienylcarbonylamino)phenyl]sulfonyl]-D, L-alanyl]amide, and esters and non-toxic salts thereof.
5. A pharmaceutical composition which comprises a compound of formula (I) according to any one of claims 1 to 4 or a non-toxic salt thereof, as active ingredient, and a pharmaceutically acceptable carrier.
6. A compound of formula (I) according to any one of claims 1 to 4 or a non-toxic salt thereof for use in the prevention and/or treatment of a disease induced by overexpression or excess activation of a gelatinase.
7. A compound of formula (I) according to any one of claims 1 to 4 or a non-toxic salt thereof for use in the prevention and/or treatment of a disease induced by overexpression or excess activation of a gelatinase which disease is a rheumatoid disease, arthroseitis, abnormal bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis, invasion or growth of tumor cells, an autoimmune disease, a disease caused by vascular emigration or infiltration of leukocytes, or arterialization.
8. Use of a compound of formula (I) according to any one of claims 1 to 4 or a non-toxic salt thereof in the manufacture

of a medicament for the prevention and/or treatment of a disease as defined in claim 6 or 7.


9. A process for the preparation of a compound of formula (I) according to any one of claims 1 to 4 or a non-toxic salt thereof, which process comprises: (A) reacting a compound of formula (II):



wherein G^1 , E^1 , J^1 and A^1 are as defined in claim 1 for G, E, J and A, with the proviso that $\text{A}^1\text{-J}^1\text{-E}^1\text{-}$, substituents of Ar in A^1 , and R^6 and R^7 in G^1 are not -COOH , -CSOH , amino, hydroxy or a group containing -COOH , -CSOH , amino or hydroxy, and R^1 is as defined in claim 1; with a compound of formula (III):



wherein $\text{R}^{2\text{-A}}$ is C1-8 alkyl, phenyl, or C1-4 alkyl substituted by phenyl, or (B) deprotecting under alkaline or acidic conditions, or hydrogenolysing a compound of formula (I-A):



wherein all the symbols are as hereinbefore defined;

optionally followed by the conversion of the compound of formula (I) thus obtained into a non-toxic salt thereof.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 30 5805

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,Y	EP-A-0 606 046 (CIBA GEIGY AG) 13 July 1994 * the whole document *	1-9	C07C311/46 A61K31/18 C07D333/38 C07D209/20
Y	WO-A-95 19956 (BRITISH BIOTECH PHARM ;BECKETT RAYMOND PAUL (GB); WHITTAKER MARK) 27 July 1995 see page 7-8: meaning of R4	1-9	
P,Y	WO-A-96 00214 (CIBA GEIGY AG ;MACPHERSON LAWRENCE JOSEPH (US); PARKER DAVID THOMA) 4 January 1996 * abstract *	1-9	
P,Y	WO-A-95 35276 (BRITISH BIOTECH PHARM ;MILLER ANDREW (GB); WHITTAKER MARK (GB); BE) 28 December 1995 see claims	1-9	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C07D A61K
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 18 September 1996	Examiner Steendijk, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure I : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 150 (01.02.1994)